We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Thermo Fisher Launches CE-IVD Marked Next-Generation TaqPath COVID-19 RNase P 2.0 Assay Kit

By LabMedica International staff writers
Posted on 27 Oct 2021
TaqPath COVID-19 RNase P 2.0 kit
TaqPath COVID-19 RNase P 2.0 kit
Thermo Fisher Scientific Inc. (Waltham, MA, USA) has launched the CE-IVD marked TaqPath COVID-19 RNase P 2.0 kit, a newly designed test that provides accurate results by compensating for current and future COVID-19 viral mutations.

The kit has been redesigned to detect active SARS-CoV-2 infections by identifying the presence of any one of eight gene targets from the virus. By surveying across multiple genes, the test can net accurate results even as mutations shift the genes they express. The TaqPath COVID-19 RNase P 2.0 kit uses an RNase P control to ensure sample integrity, quality and extraction.

The TaqPath COVID-19 RNase P 2.0 kit uses a newly designed assay to assess nasopharyngeal and nasal swab samples to detect active COVID-19 cases. The test has a turnaround time of about three hours. The first-generation test, TaqPath COVID-19 CE-IVD RT PCR Kit, has been available with a CE-IVD mark since March 2020.

"SARS-CoV-2 is continuing to mutate, and this assay is the latest in our efforts to make sure our tests are future proofed against those variants," said Manoj Gandhi, senior medical director for genetic testing solutions, Thermo Fisher Scientific. "With this product, we are offering customers the next generation of our COVID-19 diagnostic test that has inbuilt checks and balances in the face of emerging variants."

Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080

Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more